About Strongbridge Biopharma PLC
Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases. Its principal focus is to build its rare endocrine franchise, which includes product candidates for the treatment of endogenous Cushing's syndrome and acromegaly. Its product candidate, COR-003 (levoketoconazole), is a cortisol synthesis inhibitor, indicated for the treatment of endogenous Cushing's syndrome. It is conducting SONICS, a pivotal Phase III clinical trial for COR-003. Its product candidate, COR-005 (veldotide), is a multi-receptor targeted somatostatin analog (SSA) in Phase II clinical development for the treatment of acromegaly patients. Its product candidate also includes BP-2002.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: SBBP
- Previous Close: $2.60
- 50 Day Moving Average: $2.42
- 200 Day Moving Average: $3.88
- 52-Week Range: $2.00 - $6.39
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.32
- P/E Growth: 0.00
- Market Cap: $55.13M
- Outstanding Shares: 21,205,000
- Beta: 2.75
- Return on Equity: -50.52%
- Return on Assets: -47.00%
Companies Related to Strongbridge Biopharma PLC:
- Current Ratio: 6.08%
- Quick Ratio: 6.08%
What is Strongbridge Biopharma PLC's stock symbol?
Strongbridge Biopharma PLC trades on the NASDAQ under the ticker symbol "SBBP."
Where is Strongbridge Biopharma PLC's stock going? Where will Strongbridge Biopharma PLC's stock price be in 2017?
2 brokerages have issued 1-year target prices for Strongbridge Biopharma PLC's shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate Strongbridge Biopharma PLC's stock price to reach $14.00 in the next twelve months.
When will Strongbridge Biopharma PLC announce their earnings?
Strongbridge Biopharma PLC is scheduled to release their next quarterly earnings announcement on Tuesday, May, 17th 2016.
Who owns Strongbridge Biopharma PLC stock?
Strongbridge Biopharma PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include Vivo Capital LLC (14.15%), Broadfin Capital LLC (13.65%), Boxer Capital LLC (4.43%) and Tredje AP fonden (4.29%).
Who bought Strongbridge Biopharma PLC stock? Who is buying Strongbridge Biopharma PLC stock?
Strongbridge Biopharma PLC's stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Broadfin Capital LLC and Boxer Capital LLC.
How do I buy Strongbridge Biopharma PLC stock?
Shares of Strongbridge Biopharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Strongbridge Biopharma PLC stock cost?
One share of Strongbridge Biopharma PLC stock can currently be purchased for approximately $2.60.